Neurosoft Bioelectronics has raised $7.5m to advance the development of its brain-computer interface (BCI).
The Swiss company’s oversubscribed seed financing round was led by Skybound Venture Capital, with participation from other entities including PL Capital, IAG Capital Partners, and Connecticut Innovations.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Bringing Neurosoft’s funding to date to over $20m, the neurotechnology company intends to use the funds to advance its near-term goals of demonstrating the successful deployment of its BCI in human patients and progressing the system towards commercialisation in the US.
Neurosoft is one of a plethora of companies attracting investment for BCI technology. These devices are chips implanted in brain tissue that take brain signals and translate them into commands. The signals are then relayed to a secondary, external device, which then carries out a specific function.
To date, Neurosoft has evaluated its brain interface in 10 patients across two ongoing clinical trials in the US and the Netherlands, respectively.
Alongside the development of Neurosoft’s BCI, the company is building a neural data platform using information captured using its BCI to build a foundation model of the human cortex.
Comparable to the way large language models (LLMs) are trained on vast text corpora, this foundation model will be trained on large-scale neural recordings captured through its implantable devices.
In the near term, this model will “redefine what invasive BCIs can deliver for patients with severe neurological conditions”, Neurosoft stated. Longer term, the company also anticipates that this model will benefit non-invasive BCIs, serving to position brain interfaces as the “next universal layer of communication between humans and machines”.
Neurosoft’s CEO and co-founder, Nicolas Vachicouras, commented: “Our soft electrode platform, paired with a streamlined regulatory pathway, gives us access to neural data at a quality and scale no other approach can safely match today.
“That data is the foundation for improved clinical outcomes, and a cortical foundation model that will help shape the next generation of brain interfaces.”
To support the development ambitions for its BCI, Neurosoft became the inaugural partner under an agreement with Science Corporation in February 2026, giving the company the ability to develop products using the latter’s neural recording technology stack via the company’s BCI ecosystem.
According to GlobalData analysis, the global neurology devices market is projected to reach a valuation of over $25bn in 2034. In healthcare, BCI technologies are on a rapid growth course. Morgan Stanley estimates there to be an early total addressable market (TAM) of $80bn across three million US adults for BCI technology, potentially reaching $320bn with further advancements.
